High-current H beams from a filament-driven multicusp ion source.

We report the results from a new multicusp ion source (MIST-1) that produces record steady-state currents of H (1 mA) from this type of ion source with high purity (80% H ). We built MIST-1 to fulfill the stringent beam purity and beam quality requirements for IsoDAR, a proposed discovery-level neutrino experiment, requiring a 10 mA, 60 MeV/amu continuous wave (cw) proton beam on the target. IsoDAR will use a cyclotron accelerating H ions and using a novel radio frequency quadrupole (RFQ) direct injection method.

What is the potential impact of the IsoDAR cyclotron on radioisotope production: a review.

The IsoDAR collaboration is developing a high-current cyclotron for a neutrino search experiment. Designed to deliver 10 mA of 60 MeV protons, the current and power of this cyclotron far exceed those of existing accelerators, opening new possibilities for the production of radiopharmaceutical isotopes, producing very high-activity samples in very short times. The cyclotron can also be easily configured to deliver ions other than protons including 1 mA of alpha particles at 240 MeV: this flexibility gives a broad reach into new areas of isotope production.

The importance of social norms for uptake of catch-up human papillomavirus vaccination in young women.

Background: Human papillomavirus (HPV) is the cause of almost all cases of cervical cancer. The current UK government immunisation program includes free routine HPV vaccination of girls aged 12-13, with a catch-up vaccination program for 13-18-year-old girls. The aim of this study was to identify correlates of intended and actual uptake of catch-up HPV vaccination.

A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents.

Patients infected with HIV, including those with AIDS-related complex and AIDS, and failing treatment with antiretroviral agents such as zidovudine, have been evaluated following addition of trichosanthin to the antiretroviral agent regimen. This ribosomal inhibitory protein is specifically cytotoxic for HIV-infected macrophages and lymphocytes. Ninety-three patients were treated with trichosanthin, using a schedule of weekly, then monthly, intravenous injections of 1.

Neurological reactions in HIV-infected patients treated with trichosanthin.

Trichosanthin is a ribosome-inactivating protein that is being studied as a possible treatment for patients infected with human immunodeficiency virus (HIV). We report the clinical and pathological features in two patients who experienced neurological reactions to trichosanthin. Both patients were neurologically asymptomatic prior to treatment but developed coma and multifocal neurological deficits after treatment.